On May 14, 2026 Ontada, a McKesson business dedicated to real-world oncology data and insights, reported that it will present new real‑world research and introduce ON.Journey, a new oncology data solution, at ISPOR 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To continue advancing impactful real-world oncology research, Ontada is launching ON.Journey, a new portfolio of off-the-shelf, longitudinal oncology datasets. Built using oncology-specific artificial intelligence and natural language processing applied to structured and unstructured clinical data from Ontada’s proprietary dataset of electronic medical records from community oncology practices, ON.Journey enables medical affairs, health economics and outcomes research (HEOR), epidemiology, and real-world evidence teams to generate rich clinical insights with speed. With claims data natively integrated, ON.Journey allows teams to analyze treatment utilization alongside clinical outcomes—without the need for custom integration or third-party linkage.
"ON.Journey reflects our focus on delivering data solutions that help life sciences teams generate evidence with greater speed and consistency," said Christine Davis, president of Ontada. "It enables access to research-grade oncology data, supporting evolving needs across the lifecycle."
Ontada will present 12 posters at ISPOR 2026, including four that examine real-world treatment adoption, outcomes and patterns of care across community oncology populations.
"Real‑world evidence provides important insight into how cancer care is delivered," said Jessica K. Paulus, ScD, vice president, Real-World Research for Ontada. "The studies presented at ISPOR reflect our commitment to using high‑quality community oncology data to inform evidence generation and deepen understanding of care delivered in real world clinical practice settings."
Highlights of Ontada’s presence at ISPOR include:
1. Poster #HSD11: Improving Real-World Adoption of HER2-Low Therapies Through Targeted Educational Initiatives
Monday, May 18, 10:30 a.m. – 1:30 p.m. EDT
This observational study and educational initiative evaluates the use of evidence‑based educational outreach in supporting adoption of updated treatment guidelines for HER2‑low therapies.
2. Poster #MSR66: Integrating Generative Artificial Intelligence (AI) into Biostatistical Workflows for Trial Emulation: A Framework to Accelerate Real-World Evidence Generation
Monday, May 18, 4:00 p.m. – 7:00 p.m. EDT
This research outlines a framework for applying generative AI to trial‑emulation workflows to support more scalable and reproducible real‑world evidence generation.
3. Poster # RWD54: Evolution of Homologous Recombination Repair (HRR) Genetic Testing by Race Among Patients with Metastatic Prostate Cancer (mPC) in a Large Community Oncology Setting in the US, 2015 – 2024
Monday, May 18, 4:00 p.m. – 7:00 p.m. EDT
This retrospective, observational analysis uses structured electronic health record data to describe HRR genetic testing patterns by race among patients with metastatic prostate cancer.
4. Poster # HSD112: Real-World Patterns of Homologous Recombination Repair Testing of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in the US Community Oncology Setting
Wednesday, May 20, 9:00 a.m. – 11:30 a.m. EDT
This retrospective, observational cohort study examines real-world patterns of HRR genetic testing among patients, highlighting gaps in testing during earlier stages of advanced disease.
Visit the Ontada Booth (#410) at the Pennsylvania Convention Center from May 18-20 to learn more about ON.Journey and Ontada research and data capabilities.
(Press release, Ontada, MAY 14, 2026, View Source [SID1234665738])